Perlmutter Cancer Center

The purpose of the study is to evaluate the antitumor activity and safety/tolerability of etruma-based combination therapy in participants with metastatic colorectal cancer (mCRC).There are three investigational products administered in this study depending on the treatment arm: AB928 (referred to as etrumadenant and “etruma” throughout), zimberelimab (AB122; referred to as “zim” throughout), AB680. The three investigational drugs have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.